Study identifier:RDEA594-303
ClinicalTrials.gov identifier:NCT01508702
EudraCT identifier:2011-003756-39
CTIS identifier:N/A
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects with Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Gout
Phase 3
No
lesinurad, Placebo
All
214
Interventional
18 Years - 85 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Jul 2015 by Ardea Biosciences, Inc.
Ardea Biosciences, Inc.
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: lesinurad 400 mg | Drug: lesinurad Tablets, 400 mg QD |
Placebo Comparator: placebo | Drug: Placebo Tablets, Placebo QD |